ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,459.10
      1.11%
      US Tech 100
      18,522.40
      1.05%
      Dow Jones
      40,589.34
      1.64%
      Brent Oil
      79.745
      0.00%
      Bitcoin
      67,837.65
      -0.11%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Gilead Sciences Inc (GILD) Quote

      Gilead Sciences Inc

      Gilead Sciences Inc (GILD)

      DMG Mori AG
      DMG Mori AG
      DMG Mori AG
      DMG Mori AG
      Guild Esports Plc
      77.01
      0.50
      (0.65%)
      Closed July 26 4:00PM
      Delayed by 15 minutes
      76.9992
      -0.0108
      (-0.01%)
      After Hours: 7:17PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      76.9992
      Bid
      76.37
      Ask
      77.00
      Volume
      7,453,641
      75.74 Day's Range 78.29
      62.07 52 Week Range 87.865
      Market Cap
      95.93B
      Previous Close
      76.51
      Open
      76.03
      Last Trade
      20
      @
      76.99
      Last Trade Time
      Financial Volume
      $ 574,259,748
      VWAP
      77.0442
      Average Volume (3m)
      7,441,153
      Shares Outstanding
      1,245,853,209
      Dividend Yield
      3.95%
      PE Ratio
      16.94
      Earnings Per Share (EPS)
      4.55
      Revenue
      27.12B
      Net Profit
      5.67B

      About Gilead Sciences Inc

      Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.gilead.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Gilead Sciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GILD. The last closing price for Gilead Sciences was $76.51. Over the last year, Gilead Sciences shares have traded in a share price range of $ 62.07 to $ 87.865.

      Gilead Sciences currently has 1,245,853,209 shares outstanding. The market capitalization of Gilead Sciences is $95.32 billion. Gilead Sciences has a price to earnings ratio (PE ratio) of 16.94.

      Gilead Sciences (GILD) Options Flow Summary

      GILD Options Flow

      Overall Flow

      Bearish

      Net Premium

      -376k

      Calls / Puts

      540.00%

      Buys / Sells

      63.89%

      OTM / ITM

      56.10%

      Sweeps Ratio

      0.00%

      GILD Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities

      6 hours ago
      Edgar (US Regulatory)

      Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

      Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30...

      July 25 2024
      Business Wire

      Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

      – New 5-Year Clinical and Real-World Data Reinforce Biktarvy® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational...

      July 25 2024
      Business Wire

      Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024

      – PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada® for PrEP – – If Approved, Lenacapavir Would be the First...

      July 24 2024
      Business Wire

      Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia

      – RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus...

      July 22 2024
      Business Wire

      Form 8-K - Current report

      July 17 2024
      Edgar (US Regulatory)

      Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025

      Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor...

      July 17 2024
      Business Wire

      Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024

      - Late-Breaking Full Results from HIV Prevention Research of Twice-Yearly Injectable Lenacapavir - - Progress and Person-Centered Approaches Across HIV Treatment, Cure Research and Development...

      July 16 2024
      Business Wire

      EFFICACITÉ DE 100 % ET SUPÉRIORITÉ AVÉRÉES DU LÉNACAPAVIR DE GILEAD UTILISÉ DEUX FOIS PAR AN PAR RAPPORT À TRUVADA (MD) UNE FOIS PAR JOUR POUR LA PRÉVENTION DU VIH

      EFFICACITÉ DE 100 % ET SUPÉRIORITÉ AVÉRÉES DU LÉNACAPAVIR DE GILEAD UTILISÉ DEUX FOIS PAR AN PAR RAPPORT À TRUVADA (MD) UNE FOIS PAR JOUR POUR LA...

      June 26 2024
      PR Newswire (Canada)

      Honeywell Acquires CAES Systems for $1.9 Billion, Sarepta Therapeutics Surges 34%, Gilead Continues Gains

      Honeywell (NASDAQ:HON) – Honeywell announced the acquisition of CAES Systems for $1.9 billion, focusing on expanding its aerospace and defense technology operations. Under the leadership of...

      June 21 2024
      IH Market News
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      13.48924.7465650931873.5178.2970.78696447073.86173463CS
      48.339212.145645208368.6678.2966.01617030971.14506081CS
      1211.489217.538085788465.5178.2962.07744115367.74924542CS
      26-3.2308-4.0269225975380.2380.5162.07741275970.03587988CS
      520.22920.29855412270476.7787.86562.07671513973.88362797CS
      1568.059211.690165361268.9489.7457.165716325871.58923567CS
      26010.649216.05003767966.3589.7456.56837362570.38625152CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      WINTWindtree Therapeutics Inc
      $ 8.24
      (150.46%)
      		48.57M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NBSTWNewbury Street Acquisition Corporation
      $ 0.1349
      (92.71%)
      		122.1k
      YIBOPlanet Image International Ltd
      $ 2.915
      (53.43%)
      		260.07k
      CREVCarbon Revolution Public Ltd
      $ 9.00
      (45.87%)
      		8.06M
      NMHINatures Miracle Holding Inc
      $ 0.2035
      (-48.06%)
      		7.69M
      TANHTantech Holdings Ltd
      $ 0.2585
      (-47.23%)
      		6.75M
      DXCMDexCom Inc
      $ 64.00
      (-40.66%)
      		53.92M
      PSIGPS International Group Ltd
      $ 1.42
      (-31.40%)
      		716.26k
      POAIPredictive Oncology Inc
      $ 1.36
      (-27.27%)
      		6.02M
      SLNASelina Hospitality PLC
      $ 0.0305
      (-18.88%)
      		408.61M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NVDANVIDIA Corporation
      $ 113.06
      (0.69%)
      		293.33M
      SQQQProShares UltraPro Short QQQ
      $ 9.10
      (-2.88%)
      		176.49M
      SGMOSangamo Therapeutics Inc
      $ 0.8612
      (28.15%)
      		123.71M

      GILD Discussion

      View Posts
      TechandBio TechandBio 1 day ago
      Target is $100-$120 by Q2 2025

      $GILD
      👍️0
      TechandBio TechandBio 2 days ago
      HIV Prevention CURE Shot 2x a year

      Great growing oncology pipeline!

      my $80 vertical Calls from last week are looking golden!

      $GILD
      👍️0
      north40000 north40000 1 month ago
      https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602784

      "Gilead plans to share new preclinical data for an oral GLP-1 at the upcoming American Diabetes Association conference starting June 21… The asset, dubbed GS-4571, has previously demonstrated 5% to 8% weight loss in monkeys in 28 to 30 days…"
      👍️0
      north40000 north40000 1 month ago
      How about oral GLP-1 news? CNBC-TV AH today. Portal Innovations CEO interview.
      👍️0
      jondoeuk jondoeuk 2 months ago
      There is barely any move on this news. Seems the market had already written it off. O'Day needs to go, they need to rebuild in areas they have expertise in and refocus in oncology.
      👍️0
      jondoeuk jondoeuk 2 months ago
      A double whammy https://www.oncologypipeline.com/apexonco/asco-2024-full-evoke-01-result-adds-gileads-trodelvy-problems
      👍️0
      jondoeuk jondoeuk 2 months ago
      They guided that a third of revenues will be from oncology by 2030...! https://www.businesswire.com/news/home/20240530516266/en/Gilead-Provides-Update-on-Phase-3-TROPiCS-04-Study
      👍️0
      jondoeuk jondoeuk 2 months ago
      ''Using independent datasets, we validate that CD8-fit T cells (1) are present premanufacture and are associated with clinical responses in individuals treated with axicabtagene ciloleucel, (2) longitudinally persist in individuals after treatment with CAR T cells and (3) are tumor migrating cytolytic cells capable of intratumoral expansion in solid tumors.'' https://www.nature.com/articles/s43018-024-00768-3

      https://medicalxpress.com/news/2024-05-cancer-optimal-cells.html
      👍️0
      jondoeuk jondoeuk 2 months ago
      The oNKo-Innate team, along with scientists at Kite, have just published a research article https://onlinelibrary.wiley.com/doi/10.1002/cti2.1507

      Optimised manufacturing dramatically improves lentiviral transduction efficiency of primary human NK cells. The field has progressed greatly with CAR transduction rates in human NK cells (it was ~5% just a few years ago). The oNKo-Innate R&D team were able to raise CAR transduction efficiency to ~80%. After testing various NK cell sources, they conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make PB-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.

      ''No doubt CAR-NK cells have faced several challenges in oncology settings, and we hope our new findings assist researchers in addressing some of these challenges while also improving the potential for CAR-NK cell therapies in treating autoimmune disease such as lupus'' said Nicholas Huntington, PhD, oNKo-innate's CSO.
      👍️0
      jondoeuk jondoeuk 3 months ago
      The management has been substandard for many years https://www.fiercebiotech.com/biotech/gilead-gives-49b-antibody-solid-tumor-plan-unravels and https://www.fiercepharma.com/pharma/gilead-writes-24b-trodelvy-ceo-underscores-time-focused-execution
      👍️0
      jondoeuk jondoeuk 4 months ago
      IL-12 is the new IL-2! https://www.oncologypipeline.com/apexonco/xilio-gets-gilead-shaped-reprieve
      👍️0
      jondoeuk jondoeuk 4 months ago
      Interesting (preclinical) data from another company. It summarises two distinct phenotypes of cells within the product (they are manufacturing), each of which plays a different role in responding to cancer cells. Each cell population were separated based on whether they produced CD4 on their surface (CD4+ vs. CD4-). Cells negative for CD4 (CD4-) were better able to kill target cancer cells via the CD19 CAR. In contrast, CD4+ cells proliferated faster in response to CD19+ cancer cells. The two groups of cells also produced a different cytokine response in response to CAR activation.
      👍️0
      jondoeuk jondoeuk 4 months ago
      Kite Analyst & Investor Event https://s29.q4cdn.com/585078350/files/doc_events/2024/Mar/14/gild_kite-analyst-investor-event-14-march-2024.pdf
      👍️0
      jondoeuk jondoeuk 4 months ago
      I found the poster, but nothing on the design of the CARs, data on ex vivo expansion, or the percentage of CD62L+ NKTs https://www.jci.org/articles/view/83476 https://journals.aai.org/jimmunol/article/201/7/2141/107140/IL-21-Selectively-Protects-CD62L-NKT-Cells-and
      👍️0
      jondoeuk jondoeuk 4 months ago
      Some more https://www.abstractsonline.com/pp8/#!/20272/presentation/10568
      👍️0
      Monksdream Monksdream 6 months ago
      GILD new 52 week high
      👍️0
      jondoeuk jondoeuk 8 months ago
      Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

      It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.
      👍️0
      jondoeuk jondoeuk 8 months ago
      Another next-gen collab https://www.businesswire.com/news/home/20231030344859/en/Kite-and-Epic-Bio-Announce-Collaboration-to-Develop-New-Therapies-for-Cancer

      There have been a number of these over the years, but nothing seems to come of them
      👍️0
      jondoeuk jondoeuk 8 months ago
      The ACLX partnership looks like it could be be a gold mine. The ASH data completely dooms TSVT https://ash.confex.com/ash/2023/webprogram/Paper189761.html

      If Breyanzi can't take share from Yescarta, Abecma doesn't stand a chance. They made sure to point out how Carvytki is giving some Parkinsonian-like events where they have not seen it (yet). Carvykti vs ddBCMA is going to be a battle down the road.
      👍️0
      Greedy G Greedy G 11 months ago
      ~bought 9/22 $80 calls .08c
      👍️0
      jondoeuk jondoeuk 1 year ago
      Q1 results https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171789595
      👍️0
      DewDiligence DewDiligence 1 year ago
      Why is an oral prodrug of Remdesivir anything to get excited about?
      👍️0
      jondoeuk jondoeuk 1 year ago
      Obeldesivir (an oral prodrug of remdesivir) https://news.yahoo.com/gilead-details-promising-early-covid-223448308.html
      👍️0
      jondoeuk jondoeuk 1 year ago
      Kite just released ZUMA-7 results for 2L https://www.businesswire.com/news/home/20230320005701/en/Kite%E2%80%99s-Yescarta%C2%AE-CAR-T-cell-Therapy-Demonstrates-a-Statistically-Significant-Improvement-in-Overall-Survival-for-Initial-Treatment-of-RelapsedRefractory-Large-B-cell-Lymphoma

      What's big is that the trial reached five year maturity instead of just the number of deaths. Looking at it, more than 210 of the 359 (58%) are still alive at five years compared to 43% in ZUMA-1 (3L+). Sure, these were healthier patients, but the CR rate was more double (65% vs. 32%) against the standard of care. So, treatment works better in healthier patients. ZUMA-23 in 1L (against R-CHOP) is ongoing.

      The next question is whether treating healthier patients with multiple myeloma (if they can resolve supply issues with auto) can (significantly) improve PFS.
      👍️0
      fink fink 2 years ago
      Christmas sell off over, last day to lock in any paper tax loss. LOL

      Who’s losing money here?

      I think we start the trend back up into Q1
      👍️0
      fink fink 2 years ago
      It wants $90.
      I got a sell order in @88, but think it will continue up.
      Gilead is moving away from HIV and more into this cancer thingy.

      That’s not enough in my mind to justify the rise. But I do think as World central banks default and the Fed starts to absorb these other world bank’s debt on foreign currency collapse, private money has to go somewhere safe. Pharma has always been recession proof. Gilead was a great stock to load. Like LNG was 7 years ago. No end is sight there too

      Gilead still needs revenue from its new cancer avenues. HIV, they own and always will. Just already built into the $60 stock price
      👍️0
      PennyPusher786 PennyPusher786 2 years ago
      It's at a 3 year high
      👍️0
      fung_derf fung_derf 2 years ago
      Very funny that you posted this to me. I couldn't recall, but knew there were a couple of you who followed me over here. It has had a pretty nice month.

      I_luv_cydy

      Re: fung_derf post# 3875

      Tuesday, May 19, 2020 2:32:23 PM

      Post#
      3878
      of 4839
      Fung: Why do you suppose GILD keeps dropping? I'm a shareholder for a while.
      👍️0
      fink fink 2 years ago
      Nice to see GILD over $80

      Wonder if I should trim some? It’s been eating chit pie for some time.
      Still don’t see why the spike.
      👍️0
      jondoeuk jondoeuk 2 years ago
      Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers https://www.businesswire.com/news/home/20221020005633/en/Kite-and-Refuge-Biotechnologies-Announce-Exclusive-License-Agreement-for-Investigational-Gene-Expression-Platform-for-Blood-Cancers

      Some preclinical data from Refuge Bio https://jitc.bmj.com/content/8/Suppl_3/A86.2 https://jitc.bmj.com/content/9/Suppl_2/A162 https://jitc.bmj.com/content/9/Suppl_2/A164 https://jitc.bmj.com/content/8/Suppl_3/A458.2
      👍️0
      Zeppo Zeppo 2 years ago
      Gilead has underperformed for so long, given the size of the company as well, that I could encourage Bill Ackman to make a run at it.
      👍️0
      DewDiligence DewDiligence 2 years ago
      GILD details why the purportedly-positive Trodelvy data from Mar 2022 weren’t:

      https://www.businesswire.com/news/home/20220603005437/en The study met its primary endpoint of progression-free survival (PFS) with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death (median PFS 5.5 vs. 4 months; HR: 0.66; 95% CI: 0.53-0.83; P<0.0003). The first interim analysis of the key secondary endpoint of overall survival (OS) demonstrated a trend in improvement. In this context, a “trend in improvement” means non-statsig. OS could conceivably turn statsig in a later data cut, but that’s pretty unlikely.

      The viewpoint in #msg-158260565 (from 2020) has not changed.
      👍️0
      mick mick 2 years ago
      Gilead Sciences Inc (GILD)
      59.77 ? -1.79 (-2.91%)
      Volume: 10,483,423 @04/29/22 7:42:23 PM EDT
      Bid Ask Day's Range
      59.53 60.0 59.27 - 62.06
      GILD Detailed Quote
      👍️0
      jondoeuk jondoeuk 2 years ago
      ZUMA-11. Improved CAR-T responses with 4-1BB agonist utomilumab added to axi-cel. The cells were more of central and effector phenotype. No (S)AE concerns.




      👍️0
      jondoeuk jondoeuk 2 years ago
      Link to the audio recording https://investors.gilead.com/events/event-details/gilead-sciences-oncology-deep-dive
      👍️0
      jondoeuk jondoeuk 2 years ago
      Oncology Deep Dive https://investors.gilead.com/static-files/332d0c81-fa18-44fa-82d3-babf96ca12d0

      https://endpts.com/with-more-than-30-oncology-partners-gilead-lays-out-its-2030-vision-of-20-new-approvals/
      👍️0
      jondoeuk jondoeuk 2 years ago
      ZUMA-12 https://www.nature.com/articles/s41591-022-01731-4

      The CR rate was higher than standard frontline chemo, with just a single treatment vs. six cycles over about four months.

      No reason to think long-term curve won't flatten like ZUMA-1 (which was post ~two years).

      PDUFA date (for 2nd line) is April 1.
      👍️0
      mick mick 2 years ago
      GILD News: Gilead price target slashed at Barclays following new Trodelvy data 03/10/2022 05:38:07 AM
      GILD News: Current Report Filing (8-k) 03/07/2022 03:31:07 AM
      GILD News: Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer 03/07/2022 03:30:00 AM
      GILD News: Robert W. Baird Sticks to Their Hold Rating for Gilead Sciences (GILD) 03/03/2022 12:10:51 AM
      GILD News: Jefferies Thinks Gilead Sciences’ Stock is Going to Recover 03/02/2022 03:35:55 AM
      👍️0
      mick mick 2 years ago
      Gilead Sciences Inc (GILD)
      58.39 ? 0.47 (0.81%)
      Volume: 13,007,627 @03/11/22 7:41:31 PM EST
      Bid Ask Day's Range
      58.2 58.4 57.955 - 59.185
      GILD Detailed Quote
      👍️0
      mick mick 2 years ago
      Gilead Sciences Inc (GILD)
      61.33 ? 0.22 (0.36%)
      Volume: 9,751,206 @02/15/22 4:17:32 PM EST
      Bid Ask Day's Range
      61.15 61.33 60.97 - 61.515
      GILD Detailed Quote
      👍️0
      mick mick 2 years ago
      Gilead Sciences Inc (GILD)
      63.9 ? -1.49 (-2.28%)
      Volume: 12,392,843 @02/04/22 7:58:42 PM EST
      Bid Ask Day's Range
      63.8 64.0 63.8722 - 65.61
      GILD Detailed Quote
      👍️0
      DewDiligence DewDiligence 2 years ago
      GILD owes ViiV* $1.25B+_3% royalty on_US Biktarvy sales, as a result of a patent settlement:

      https://www.gsk.com/en-gb/media/press-releases/gsk-announces-settlement-between-viiv-healthcare-and-gilead-sciences/

      The 3% royalty is a pretty big deal since Biktarvy’s had annualized US sales of $8.4B(!) in 4Q21.

      * ViiV is a JV comprised of: GSK (76.5%); PFE (13.5%); and Shionogi (10%).
      👍️0
      DewDiligence DewDiligence 2 years ago
      GILD 4Q21 results…

      PR:
      https://investors.gilead.com/static-files/107ab0e3-735c-4760-882f-c3647ea97ce2

      CC slides:
      https://investors.gilead.com/static-files/afa262c5-7eed-4944-81f5-3c2d09489d1b
      👍️0
      mick mick 3 years ago
      https://www.otcmarkets.com/stock/GILD
      👍️0
      DewDiligence DewDiligence 3 years ago
      GILD vs BMY in LBCL CAR-T—who has the edge?

      https://www.fiercepharma.com/pharma/bristol-myers-squibb-breyanzi-gilead-yescarta-lock-horns-car-t-therapy-earlier-lymphoma

      Both Yescarta and Breyanzi are poised to take share from stemcell transplants.
      👍️0
      mick mick 3 years ago
      https://www.otcmarkets.com/stock/GILD
      👍️0
      dhbuzz dhbuzz 3 years ago
      GILD and MTNB have been working on ORAL remdesivir ,results to date look outstanding ,if this is green lighted by FDA,should really give GILD a SP jump as well as MTNB

      GLTA
      👍️0
      DewDiligence DewDiligence 3 years ago
      VIR/GILD start phase-2 trial testing quadruple regimen of VIR-2218; GS-9688; Opdivo; and Vemlidy (TAF) in (both nuc-suppressed and viremic) HBV patients:

      https://finance.yahoo.com/news/vir-biotechnology-announces-initiation-phase-133000267.html

      I’m not sure why it took almost a year for this trial to begin enrolling patients—the PR announcing the collaboration was issued on 1/12/21.

      Please see #msg-160854272 for background.
      👍️0
      Michel Michel 3 years ago
      I Agree: https://www.griproom.com/fun/pfizers-covid-pill-might-not-be-as-great-as-theyre-saying


      Brilacidina y Remdesivir
      👍️0
      Ultimate01 Ultimate01 3 years ago
      Showtime this week! Brilacidin is a BEAST. Remdesivir needs Brilicidin to remain relevant and in the market but Brilacidin does not need Remdesivir. Gilead has the opportunity to remain relevant and go down in history as the company that helped end the pandemic, or the company that missed the greatest opportunity.
      👍️0

      Your Recent History

      NASDAQ
      GILD
      Gilead Sciences
      Delayed Upgrade Clock